2026-09-09 17:50
Biovica delivered 56% sales growth in the first quarter, driven by strong Pharma Services momentum, while taking decisive actions to streamline operations, strengthen leadership, and position the company for its next phase of growth.
2026-06-17 08:00
Strong growth provides the platform for the next commercial phase
2026-03-18 08:00
46% growth with strong momentum in the USA and for Pharma Services Q3 (Nov 2025–Jan 2026) (comparison figures are for the same period 2024/2025) Q1–Q3 (May 2025–Jan2026) (comparison figures are for the same period 2024/2025) Significant events during...
2025-12-18 08:30
Positioned for growth in Pharma Services and in the USA
2025-09-11 08:00
Partnership agreement with Tempus and continued organic growth in the USA
2025-03-13 08:00
Quarterly sales doubled, expanding market potential exponentially
2024-12-12 08:00
Significant events during the second quarter Significant events after the end of the period Webcast:When: 12/12 2024 kl. 15.00 CETWhere: registration via: Biovica Q2 Earnings Call, Thu, Dec 12, 2024 at 3 PM CETBroadcast language: in English CEO’s comments...
2024-09-12 10:25
Significantly increased sales in the USA and much improved cash flow
2024-09-12 08:00
Significantly increased sales in the USA and much improved cash flow
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects